• Title/Summary/Keyword: 방사성동위원소 치료

Search Result 43, Processing Time 0.026 seconds

A study of Brachytherapy for Intraocular Tumor (안구내 악성종양에 대한 저준위 방사선요법에 관한 연구)

  • Ji, Gwang-Su;Yu, Dae-Heon;Lee, Seong-Gu;Kim, Jae-Hyu;Ji, Yeong-Hun
    • The Journal of Korean Society for Radiation Therapy
    • /
    • v.8 no.1
    • /
    • pp.19-27
    • /
    • 1996
  • I. Project Title A Study of Brachytherapy for intraocular tumor II. Objective and Importance of the project The eye enucleation or external-beam radiation therapy that has been commonly used for the treatment of intraocular tumor have demerits of visual loss and in deficiency of effective tumor dose. Recently, brachytherapy using the plaques containing radioisotope-now treatment method that decrease the demerits of the above mentioned treatment methods and increase the treatment effect-is introduced and performed in the countries, Our purpose of this research is to design suitable shape of plaque for the ophthalmic brachytherapy, and to measure absorbed doses of Ir-192 ophthalmic plaque and thereby calculate the exact radiation dose of tumor and it's adjacent normal tissue. III. Scope and Contents of the project In order to brachytherapy for intraocular tumor, 1. to determine the eye model and selected suitable radioisotope 2. to design the suitable shape of plaque 3. to measure transmission factor and dose distribution for custom made plaques 4. to compare with the these data and results of computer dose calculation models IV. Results and Proposal for Applications The result were as followed. 1. Eye model was determined as a 25mm diameter sphere, Ir-192 was considered the most appropriate as radioisotope for brachytherapy, because of the size, half, energy and availability. 2. Considering the biological response with human tissue and protection of exposed dose, we made the plaques with gold, of which size were 15mm, 17mm and 20mm in diameter, and 1.5mm in thickness. 3. Transmission factor of plaques are all 0.71 with TLD and film dosimetry at the surface of plaques and 0.45, 0.49 at 1.5mm distance of surface, respectively. 4. As compared the measured data for the plaque with Ir-192 seeds to results of computer dose calculation model by Gary Luxton et al. and CAP-PLAN (Radiation Treatment Planning System), absorbed doses are within ${\pm}10\%$ and distance deviations are within 0.4mm Maximum error is $-11.3\%$ and 0.8mm, respectively. As a result of it, we can treat the intraocular tumor more effectively by using custom made gold plaque and Ir-192 seeds.

  • PDF

Radiation Safety Consideration Regarding the Treatment which uses the Radioactive Substance (방사성물질을 이용한 치료의 안전관리 고찰)

  • Lim, Cheong-Hwan;Kim, Seung-Chul;Lee, Gui-Won
    • The Journal of the Korea Contents Association
    • /
    • v.8 no.11
    • /
    • pp.217-224
    • /
    • 2008
  • Is trend that treatment that use isotope of radioactive substance increases from 1964 to now steadily. Bursting tube state solidified accordingly. But, do not establish treatment ward in presence at a sickbed by means that present regulation and system escape this as well as possession that exert negative impact in treatment action preferably is and is treating by radioactivity of small quantity, treatment air by that do not detain many sickers without equaling the institution although there is treatment ward keeps fair death anniversary and is in reservation stand-by status. To possess about 10 therapy rooms including existing sickroom in the institute of nuclear energy recently is looked but is waiting for an opportunity for treatment during suitableness time yet indeed even as that operate 57 radiation isotope therapy rooms all in about 28 hospitals in present domestic state is solveded. Therefore, radiation safety supervision by medical treatment action that treat as radioactive substance may need more active effort. Make mandatory to equipment that hospital which correspond to present the third medical examination and treatment must equip, or effort about more active system improvement may have to be about equipment that enforce this.

Quality Control Tests and Acceptance Criteria of Diagnostic Radiopharmaceuticals (진단용 방사성의약품의 품질관리시험 및 기준)

  • Park, Jun Young
    • Korean Journal of Clinical Laboratory Science
    • /
    • v.53 no.1
    • /
    • pp.1-10
    • /
    • 2021
  • Radiopharmaceuticals are drugs that contain radioisotopes and are used in the diagnosis, treatment, or investigation of diseases. Radiopharmaceuticals must be manufactured in compliance with good manufacturing practice regulations and subjected to quality control before they are administered to patients to ensure the safety of the drug. Radiopharmaceuticals for administration to humans need to be sterile and pyrogen-free. Hence, sterility tests and membrane filter integrity tests are carried out to confirm the asepticity of the finished drug product, and a bacterial endotoxin test conducted to assess contamination, if any, by pyrogens. The physical appearance and the absence of foreign insoluble substances should be confirmed by a visual inspection. The chemical purity, residual solvents, and pH should be evaluated because residual by-products and impurities in the finished product can be harmful to patients. The half-life, radiochemical purity, radionuclidic purity, and strength need to be assessed by analyzing the radiation emitted from radiopharmaceuticals to verify that the radioisotope contents are properly labeled on pharmaceuticals. Radiopharmaceuticals always carry the risk of radiation exposure. Therefore, the time taken for quality control tests should be minimized and care should be taken to prevent radiation exposure during handling. This review discusses the quality control procedures and acceptance criteria for a diagnostic radiopharmaceutical.

The Quality Control of Gamma Camera in Nuclear Medicine (핵의학분야(核醫學分野)에서의 Gamma Camera의 품질관리(品質管理)에 관(關)한 연구(硏究))

  • Kim, Jang-Hee;Hong, Seong-Woon
    • The Korean Journal of Nuclear Medicine
    • /
    • v.17 no.1
    • /
    • pp.79-84
    • /
    • 1983
  • 우리나라에 방사성동위원소가 진단 및 치료에 이용된지 20여년이 되였으며 특히 80년대에 들어와서는 Scintillation Camera의 급격한 증가가 이뤄지게 되었다. 그러나 많은 기기의 증가로 품질관리가 필요하게 되었다. 핵의학장비의 품질관리 목적은 장비기능의 정상여부를 조기에 발견하여 항상 균등한 질의 영상을 재현시켜 진단을 보다 정확하게 하는데 있다. 따라서 Scintillation Camera를 사용할 때 사용자는 기계의 기능과 성능을 항상 정확하게 파악하여 적절한 대책을 세워 보다 정확한 영상을 얻을 수 있도록 해야 한다. 저자들은 이러한 점을 고러하여 Scintillation Camera의 품질관리에 대한 원칙과 기술적인 문제점을 문헌고찰과 함께 보고하는 바이다.

  • PDF

Radioisotope Treatment for Benign Strictures of Non-vascular Luminal Organs (비혈관성 관강 장기의 양성 협착 질환의 방사성동위원소 치료)

  • Shin, Ji-Hoon
    • Nuclear Medicine and Molecular Imaging
    • /
    • v.40 no.2
    • /
    • pp.106-112
    • /
    • 2006
  • Tissue hyperplasia is one of the most frequently encountered complications when self-expanding metallic stents are placed in benign non-vascular luminal organ strictures, thus causing restenosis of the lumen. The investigators postulated that ionizing irradiation could be applied to prevent restenosis caused by tissue hyperplasia in non-vascular luminal organs as it reduced coronary or peripheral arterial narrowing successfully. The authors combined $\beta$-irradiation using $^{188}Re-MAG_3$ solution with balloon dilation for animal and clinical studies because this new treatment approach had the advantages such as low penetration depth of $\beta$-ray, self-centering irradiation, and mechanical effect of balloon dilation over using $\gamma$-irradiation with afterloading devices in this article, the concept and mechanism of radioisotope balloon dilation, and animal and clinical studies using radioisotope balloon dilation are reviewed.

Regulatory Problems in Radionuclide Therapy and Suggestions for Systematic Improvement (방사성동위원소 치료의 제도적 문제점과 개선)

  • Jeong, Jae-Min
    • Nuclear Medicine and Molecular Imaging
    • /
    • v.40 no.2
    • /
    • pp.53-57
    • /
    • 2006
  • Radionuclide therapy has been used for more than 50 years and proved to be a safe and effective modality. However, the patients' right to have the excellent medical service is seriously disturbed by excessive regulations of government institutions such as Korea Institute of Nuclear Safety (KINS), Health Insurance Review Agency (HIRA) and Korea Food and Drug Administration (KFDA). For example, the patients should wait for more than 6 months to have I-131 treatment in many hospitals it is strongly recommended to mitigate the regulations to resonable levels to solve the problems. If HIRA allow the hospitals to charge reasonable rate for radionuclide therapy room, then more hospitals would invest to build the radionuclide therapy rooms and the patients' waiting time would decrease. The waiting time would also decrease, if KINS allow 2 patients to share a radionuclide therapy room. Finally, it is strongly recommended to lower the threshold for approval of new therapeutic radiopharmaceuticals by KFDA, which would allow new effective therapeutic raoiopharmaceuticals to be introduced to clinical practices more easily.

Medical Therapeutic Effect of Hyperthyroidism - Comparison of antithyroid therapy and $^{131}I$ Therapy - (갑상선기능항진증(甲狀腺機能亢進症)의 내과적(內科的) 치료효과(治療效果) - 방사성동위원소(放射性同位元素) ($^{131}I$)치료(治療)와 항갑상선제(抗甲狀腺劑) 치료(治療)의 비교검토(比較檢討) -)

  • Lee, Kyu-Bo
    • The Korean Journal of Nuclear Medicine
    • /
    • v.14 no.2
    • /
    • pp.35-40
    • /
    • 1980
  • In order to compare the therapeutic effect as well as side effects between antithyroid therapy and radioiodine therapy in hyperthyroidism, the author evaluated 111 cases of hyperthyroidism which were composed of 57 patients with antithyroid treatment, 23 patients with combined treatment comprising of antithyroid and radioactive iodine ($^{131}I$) and 31 patients with treatment of $^{131}I$ alone. The $^{131}I$ treatment was limited to older age, above 20 years of age, and not employed in patients with pregnancy and lactation. The patients treated with antithyroid belonged to relatively younger age, and also milder in symptoms and thyroid function tests. The remission rate of antithyroid therapy group was 97.8% within 16 months. Among them the early remission rate occured within 4 months was found to be 21.7%. The combined therapy group, having prescribed more severe cases, showed the remission rate to be 75% within 16 months. The remission rate of $^{131}I$ therapy group revealed 90.9% within 16 months. Among them the early remission rate taking place within 4 months disclosed 16.7%. The side effects of antithyroid drug, propylthiouracil, were noted as follows: itching (2.7%) skin rashes (1.3%), and adverse enlargement of goiter (10.7%). The side effects $^{131}I$ therapy were transient hypothyroidism(3.9%) permanent hypothyroidism (7.8%) and itching (2.0%).

  • PDF

Synthesis of PET and SPECT Radiotracers Using Inverse Electron-demand Diels-Alder Reaction (Inverse Electron-demand Diels-Alder 반응을 이용한 핵의학 영상 프로브의 합성 및 활용)

  • Mushtaq, Sajid;Jeon, Jongho
    • Applied Chemistry for Engineering
    • /
    • v.28 no.2
    • /
    • pp.141-152
    • /
    • 2017
  • Inverse electron-demand Diels-Alder reactions (IEDDA) between tetrazine derivatives and strained dienophiles have attracted a lot of attention for the efficient conjugation of biomolecules, polymers, and nanomaterials. Excellent specificity, exceptionally fast reaction rate, and biocompatibility are key features of IEDDA. Therefore, it has also been applied to the development of new labeling methods using several radioisotopes and development of radiotracers to carry out various nuclear imaging as well as therapeutic studies. The purpose of this review is to introduce the reader to the recent advances and applications of IEDDA in the fields of radiochemistry and nuclear medicine.

고 선량율 근접 및 온열치료 병용 삽입관의 제작과 특성

  • 추성실;김성규
    • Proceedings of the Korean Society of Medical Physics Conference
    • /
    • 2003.09a
    • /
    • pp.52-52
    • /
    • 2003
  • 악성종양을 치료하는 방법중 방사선과 온열요법은 가장 강력한 치료방법으로 연구되어왔으며 이를 병용함으로 서 상승효과를 얻을 수 있다. 인체조직에 41$^{\circ}C$ 이상의 열을 가하면 세포질의 단백질변성으로 세포에 손상을 주어 세포가 사멸하게 되며 세포의 생존율은 가열시간 즉 열량에 따라 지수적으로 감소한다. 온열은 세포주기중 방사선 저항성이 매우 큰 DNA 합성시기와 산도가 높을 때 감수성이 매우 크기 때문에 방사선과 병용요법은 상호 상승효과를 가져온다. 이와 같이 온열을 이용한 악성종양의 치료가능성은 생물학적 기초연구와 임상시험에서 경이적인 효과를 얻을 수 있었으나 아직 까지 가열방법과 온도분포측정이 큰 과제로 남아있으며 주위건강조직의 가열을 피하면서 인체 깊은 곳에 존재하는 종양에만 집중 가열하는 방법인 삽입형 온열치료방법에 대한 연구가 집중되었다. 한편 방사선 치료방법은 주위 건강조직의 피폭을 최소로 줄이고 종양에만 집중 조사가 요구되며 자궁암, 유방암, 뇌암등 부피가 작고 집중적 치료를 요하는 종양은 방사성동위원소를 이용한 근접 삽입치료 (Brachyradiotherapy)가 큰 효과를 나타내고 있다 방사선과 온열의 병행 치료를 위하여 방사선 삽입 치료에 사용한 선원 삽입관을 그대로 두고 삽입관 속에 방사성 동위원소 대신 온열 전극을 넣어 열을 가하는 방사선 온열 병용치료방법을 고안하였으며 방사선과 온열병용에 사용할 최적 삽입관의 제작과 이에 따른 온도분포의 측정과 최적삽입방법을 결정하였다. 방사선 삽입치료용 폴리에찌렌 삽입관의 외부에 금박을 입혀 라디오파 첨극을 삽입할 때 서로 연결되도록 고안 제작함으로서 방사선 삽입치료와 자입식 온열치료를 동시에 만족하게 수행할 수 있는 병용삽입관 (Flexible thermoradiotherapy probes)을 제작하였다. 전도율이 큰 금박부위가 직접 조직에 접촉됨으로 라디오파의 전달이 용이하며 금박의 길이를 2 cm 에서 5 cm 로 구분제작 함으로서 종양의 크기와 모양에 따라 선택할 수 있도록 하였다. 라디오파를 이용한 온열분포의 측정은 인체조직과 전기적 특성이 비슷한 물질인 한천 팬텀 제작하여 사용하였으며 온도분포 측정은 열전대와 서머그람으로 시행하였다. 생체조직 내에서의 온도분포와 온열효과를 관찰하기 위하여 직접 개의 뇌를 이용하여 시행하였으며 4 개의 전극을 이용하여 43$^{\circ}C$로 50분간 가열하고 일주일후 개를 회생시켜 개 뇌에 대한 조직학적 검사를 시행하였다. 한편 팬텀 표면에서 중앙부로 안테나 길이가 2 cm 인 4 개의 전극을 1 cm 간격으로 정사각형이 되도록 삽입하여 가열하였을 때 90% 등온곡선이 반경 1.25의 원형으로 균일하게 분포되었고 종단면상 삽입관의 길이에 따라 균일한 온도분포가 이루어졌다. 전극을 2 cm 간격으로 삽일 하였을 때 90% 등온곡선이 1.75 반경으로 거의 4 각형의 균일한 분포를 얻었으나 전극의 간격이 증가하면 전도율이 떨어져서 전극 중심부에 불균일한 온도분포를 형성하였다. 동물실험에서 정상 개의 뇌 실질에 자입하여 직접 정방형의 중심을 43$^{\circ}C$로 유지하며 50분간 온열 요법을 시행한 후 관찰한 조직병리학적 소견은 liquefactive necrosis, pyknosis of neuronal element 및 polymorphonuclear leukocytes들의 회백질에서 급성기에 관찰되었고 liquefactive necrosis 주위에 lipid-laden macrophage들이 관찰됨이 공통적인 특정이었으며 후기변화로 괴사조직 주위로 신경교세포의 증식이 관찰되었다.

  • PDF